This study reports an adult AML-M4 patient with atypical chromosomal aberrations present in all dividing bone marrow cell at diagnosis: t(1;8)(p32.1;q24.2), der(9)t(9;10)(q22;?), and ins(19;9)(p13.3;q22q34) that may have originated transcripts with leukemogenic potential. Acute non-lymphocytic or myelogenous leukemia (ANLL or AML) represents a hematopoietic malignancy characterized by abnormal cell proliferation and stalled differentiation leading to the accumulation of immature cells in the marrow itself, in peripheral blood and eventually in other tissues. Primary chromosomal abnormalities in AML are highly specific and considered to be associated with leukemic transformation, whereas secondary changes are less specific and probably contribute to disease progression. As reviewed by Chen and Sandberg. (2002) , the common chromosomal abnormalities in the acute myelomonocytic leukemia FAB (French-American-British Cooperative Group) type M4 include monosomy 5 or del(5q), monosomy 7 or del(7q), trisomy 8, t(6;9) (p23;q34), and rearrangements involving the Mixed Lineage Leukemia (MLL) gene mapped at 11q23 [del(11) (q23); t(9;11)(p22;q23), t(11;19)(q23;p13)], and Core Binding Factor B (CBFβ) mapped at 16q22 [del(16)(q22), inv(16)(p13q22), t(16;16)(p13;q22)]. Less frequently, trisomy 4, trisomy 22, t(8;21)(q22;q22) and rearrangements with breakpoints in 3q21, 3q26, 8p11, 11p15 and 11q13 have also been reported in FAB M4 type patients
Acute non-lymphocytic or myelogenous leukemia (ANLL or AML) represents a hematopoietic malignancy characterized by abnormal cell proliferation and stalled differentiation leading to the accumulation of immature cells in the marrow itself, in peripheral blood and eventually in other tissues. Primary chromosomal abnormalities in AML are highly specific and considered to be associated with leukemic transformation, whereas secondary changes are less specific and probably contribute to disease progression. As reviewed by Chen and Sandberg. (2002) , the common chromosomal abnormalities in the acute myelomonocytic leukemia FAB (French-American-British Cooperative Group) type M4 include monosomy 5 or del(5q), monosomy 7 or del(7q), trisomy 8, t(6;9) (p23;q34), and rearrangements involving the Mixed Lineage Leukemia (MLL) gene mapped at 11q23 [del(11) (q23); t(9;11)(p22;q23), t(11;19)(q23;p13)], and Core Binding Factor B (CBFβ) mapped at 16q22 [del(16)(q22), inv(16)(p13q22), t(16;16)(p13;q22)]. Less frequently, trisomy 4, trisomy 22, t(8;21)(q22;q22) and rearrangements with breakpoints in 3q21, 3q26, 8p11, 11p15 and 11q13 have also been reported in FAB M4 type patients (Mitelman Database of Chromosome Aberration in Cancer 2006). Karyotype is generally an important prognostic factor in AML, a favorable prognosis being associated with minor karyotypic changes, low frequency of abnormal bone marrow cells and changes specifically involving the CBFβ gene, while a poor prognosis is associated with a monosomy 5, monosomy 7, trisomy 8, abnormalities in the 3q andchanges specifically involving the MLL gene (Strout et al., 1999; Chen and Sandberg, 2002) . Atypical cytogenetic findings have been sporadically reported in AML-M4 but the scarcity of these abnormalities poses a challenge to using such changes as prognostic factors, reinforcing the need for the collection of clinical data on rare events.
In this paper we describe an adult male patient diagnosed with hematological and clinical characteristics of AML-M4 who presented good response to treatment. Cytogenetic analyses revealed atypical structural aberrations not previously described in AML-M4 that could only be properly identified using G-banding, spectral karyotyping (SKY) and metaphase fluorescence in situ hybridization (FISH) analyses.
Bone marrow aspirate withdrawn at diagnosis of the disease was used for classical and molecular cytogenetic analysis after a 24-h non-stimulated culture in RPMI1640 medium with 20% fetal calf serum. G-banding (20 cells) and spectral SKY analyses (10 cells) were performed as de- Genetics and Molecular Biology, 30, 1, 6-9 (2007) Copyright by the Brazilian Society of Genetics. Printed in Brazil www.sbg.org.br scribed in Vendrame-Goloni et al. (2003) and the karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN, 2005) . The metaphase FISH assays were performed according to a standard protocol (Estécio et al., 2002) and used the TelVysion 8q and the LSI C-MYC probes labeled with SpectrumOrange (Vysis/Abbott Laboratories) and a 4-cosmid contig mapped just centromeric to theTFP3 (E2A) gene (Boomer et al., 2001 ) which was labeled with SpectrumGreen.
The patient was a 32-year-old man who presented to the Austa Hospital (São José do Rio Preto, São Paulo state, Brazil) in October 2000 with fever, petechiae, cough and fatigue. He had no hepatosplenomegaly or lymph node enlargement but his hemogram showed pancytopenia, with 8.2 g/dL of hemoglobin, a hematocrit of 25.3% and a white blood cell count of 2 x 10 9 /μL (8% neutrophils, 41% lymphocytes and 46% blast cells). A bone marrow aspirate showed hypercelullarity with 78% of myeloblasts and monocyte lineage cells. Cytochemical tests showed 44% Sudan-Black positive and 10% periodic acid Schiff (PAS) positive blast cells and 32% of non-erythroid blast cells were positive for non-specific alpha-naphylacetate esterase. The patient reported no previous exposure to cytotoxic or mutagenic agents. The diagnosis of de novo acute myeloid leukemia FAB classification type M4 was made. This study was approved by the ethics committee of the IBILCE-UNESP, São José do Rio Preto, SP, Brazil.
Cytogenetic analysis using G-banding showed structural changes interpreted as two reciprocal translocations, t(1;8)(p32;q24) and t(9;19)(q22;p13), in the 20 cells analyzed.Independent SKY analysis detected four abnormal chromosomes [i.e. del(1)(p32), der(8)t(1;8)(p32.1;q24.2), der(9)t(9;10)(q22;?) and der(19)t(9;19)(q22;p13.3)] in the 10 cells analyzed by this technique ( Figure 1A ). These findings were supported by the metaphase FISH studies performed using the C-MYC, TelVysion 8q and 19p13.3 contig probes. The TelVysion probe recognized homology with the normal 8q and with the terminal region of the short arm of the chromosome designated as del(1)(p32) in the SKY analysis ( Figures 1B, C) , therefore confirming the reciprocal translocation t(1;8) detected by G-banding analysis. The MYC gene sequence was also detected in the der(1), indicating that the 8q24 breakpoint was proximal to this gene ( Figure 1D ). The 19p13.3 contig probe recognized homology with the distal region of the p-arm of the normal chromosome 19 and the end of the rearranged arm of the abnormal chromosome 19, distal to the material identified as originating from chromosome 9 (Figures 1B, C) . Therefore, the chromosome postulated previously to be der(19)t(9;19) was identified as an ins(19;9)(p13.3;q22 q34) with the breakpoint proximal to the TFPT (E2A) gene. On the basis of all the tests (summarized in Figure 1E ), the patient's karyotype was interpreted as 46,XY,t(1;8) (p32.1;q24.2), der(9)t(9;10)(q22;?), ins(19;9)(p13.3;q22 q34).
The patient was submitted to remission-induction chemotherapy with 100 mg/m 2 /day of intravenous cytosine arabinoside (ara-C) continuously for 7 days and 12 mg/m 2 /day of intravenous idarubicin for 2 days. Complete remission was achieved after the first course of induction chemotherapy. The patient then received three courses of consolidation chemotherapy consisting of 2 mg/m 2 /day of ara-C for 4 days and 45 mg/m 2 /day of doxorubicin for 2 days followed by non-related allogeneic bone marrow transplantation. The patient has remained disease-free as at January 2006.
Clinical descriptions of atypical cytogenetic cases are rare but can be useful for clinicians. An inv(4)(p14q27) was described as the sole karyotypic anomaly at diagnosis in the bone marrow from an adult patient who responded poorly to chemotherapy and had a short survival time (Benasayag et al., 2002) .
At the time of the AML-M4 diagnosis our patient presented a karyotype with three atypical clonal abnormalities, t(1;8)(p32.1;q24.2), der(9)t(9;10)(q22;?), and ins(19;9) (p13.3;q22q34). Interestingly, these abnormalities involved four breakpoints (1p32, 8q24.2, 9q22, and 19p13.3) reported as being disrupted in a few AML M4 cases. Of these breakpoints the 9q22 breakpoint has most often been reported to be involved in anomalies, although in the majority of patients it has occurred in association with other major changes (Strout et al., 1999) such as t(8;21)(q22;q22), t(12;19)(p11;p11), t(16;21)(p11;q22), del(11(q23) and del(12)(p11). In the literature, only three AML-M4 patients have shown single deletions involving this region. The 9q22 regionharbors numerous potential leukemogenic genes, such as the HEMGN (EDAG) gene which is sequentially expressed at active hematopoietic sites and downregulated during the differentiation of blood cells (Yang et al., 2001 ) and the NOR-1 (NRA3) gene which is an`orphan member' of the nuclear hormone receptor superfamily implicated in cell proliferation, differentiation and T-cell apoptosis, although the mechanisms controlling transcriptional activation, coactivator recruitment and agonistmediated activation still remain obscure (Laflamme et al., 2003) .
The other three breakpoints (1p32, 8q24.2 and 19p13.3) detected in our patient have been less frequently reported in AML-M4. Deletions and translocations involving 1p32 are common in T-ALL (T-cell acute lymphoblastic leukemia) but only three AML-M4 cases are listed in the Cancer Genome Anatomy Project (Mitelman Database of Chromosome Aberration in Cancer 2006; Strout et al., 1999) , two with t(1;11)(p32;q23) and one with t(1;21) (p32;q22). Numerous genes clustered at 1p32 are potential candidates in leukemogenesis, among them the TAL1 gene (Perotti et al., 1999; Carlotti et al., 2002) and the AF1P gene which was investigated in one of the AML-M4 pa-tients (Cherry et al., 2001) . Breakpoints at 8q24.2, in association with multiple chromosome abnormalities have been reported in two AML M4 patients (Strout et al.1999 ) and may affect the expression of the MYC oncogene. In our patient, the MYC gene was confirmed as translocated to the derivative chromosome 1, but specimens from the patient were not available for protein expression assessment. Abnormalities involving chromosome band 19p13.3 are common in ALL and AML. The chromosome 19 insertion breakpoint was proximal to TFPT (TCF3, E2A) which suggested that the MLLT1 (ENL) gene could be a target for disruption. The MLLT1 gene has been causally related to leukemias including AML-M4 (Strout et al.,1999; Rubnitz and Look, 1998; Brambillasca et al., 2001; Kopf and Miskin, 2005) . All these structural abnormalities are potentially associated with deregulation of genes playing key roles in cell proliferation and differentiation, either by juxtaposing these genes to constitutively active foreigner promoters or producing fusion transcripts with leukemogenic potential. However the nature of the specific gene(s) altered in our patient remains unknown.
In conclusion, our study indicates that a combination of techniques was essential to reveal cryptic chromosome rearrangements in this leukemia patient. Importantly, despite presenting a complex karyotype, which is recognized as poor prognostic factor in leukemia (Chen and Sandberg, 2002; Ferrant et al., 1997) , the patient showed an excellent response to treatment and has remained in remission for over 5 years.
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